Evaluation of favipiravir in the treatment of COVID-19 based on the real-world
| Autor: | Haitao Chen, Sensen Yang, Changyuan Yang, Jisheng Chen, Weishang Deng, Zhikun Qiu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Disease Favipiravir favipiravir Microbiology Virology Internal medicine Medicine Humans In patient Clinical efficacy Randomized Controlled Trials as Topic business.industry SARS-CoV-2 Therapeutic effect Amides COVID-19 Drug Treatment Clinical trial Infectious Diseases Treatment Outcome Antiviral agents covid-19 Meta-analysis Pyrazines Other business Meta-Analysis viral clearance |
| Zdroj: | Expert Review of Anti-Infective Therapy article-version (VoR) Version of Record |
| ISSN: | 1744-8336 |
| Popis: | Background The role of favipiravir (FVP) as a COVID-19 treatment is recognized but not fully elucidated. We aimed to evaluate whether FVP has definite clinical efficacy and safety in the treatment of COVID-19. Methods International and Chinese databases were searched for randomized controlled clinical trials evaluating FVP for the treatment of COVID-19. A meta-analysis was performed and published literature was synthesized to evaluate the corresponding therapeutic effects. Results We included 13 studies (1430 patients in total). Meta-analysis showed that patients with mild-to-moderate disease treated with FVP had a significantly higher viral clearance rate than those in the control group 10 and 14 days after initiation of treatment [RR: 1.13 (95% CI: 1.00, 1.28), P = 0.04; I2 = 39% for day 10 and RR: 1.16 (95% CI: 1.04, 1.30), P = 0.008; I2 = 38% for day 14] and a significantly shorter hospital stay [MD: −1.52 (95% CI: −2.82, −0.23), P = 0.02; I2 = 0%]. Conclusions FVP significantly promotes viral clearance and reduces the hospitalization duration in mild-to-moderate COVID-19 patients, which can reduce the risk of severe disease outcomes in patients. However, more importantly, the results showed no benefit of FVP in severe patients, and caution should be taken regarding the treatment options of FVP in severe patients. PLAIN LANGUAGE SUMMARY The urgent need to identify effective interventions to treat novel coronavirus infections is a major challenge. The role of favipiravir (FVP) as a COVID-19 treatment is recognized but not fully elucidated. Our study showed a significant correlation between viral clearance and the promotion of clinical improvement with FVP in mild-to-moderate patients, which is significant for reducing the length of hospital stay of patients, reducing the risk of patients progressing to severe disease, thereby reducing mortality. However, the results showed no benefit of FVP in severe patients and the conclusion of this study still needs to be further verified by clinical trials with large samples. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|